<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129599">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02102776</url>
  </required_header>
  <id_info>
    <org_study_id>20131201</org_study_id>
    <nct_id>NCT02102776</nct_id>
  </id_info>
  <brief_title>Intraoperative Mitomycin C Versus Amniotic Membrane Transplantation After Extensive Pterygium Excision</brief_title>
  <acronym>Pterygium</acronym>
  <official_title>Intraoperative Mitomycin C Application Versus Amniotic Membrane Transplantation After Extensive Pterygium Excision: A Web-based Multi-center Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized multi-center clinical trial is to compare the efficacy and
      safety of intraoperative mitomycin C(MMC) application with amniotic membrane
      transplantation(AMT) after extensive excision for primary pterygium. The investigators will
      also evaluate particular risk factors related to pterygium recurrence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with primary pterygium will be randomly assigned to undertake extensive pterygium
      excision followed by intraoperative mitomycin C application or amniotic membrane
      transplantation in five clinical centers. Multi-center collaboration and quality monitoring
      will be based on a website designed especially for this study. The patients will be followed
      at least 12 months. Recurrence was considered as a fibrovascular ingrowth beyond the limbus
      with conjunctival drag.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Recurrence of pterygium</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healing time of corneal epithelium</measure>
    <time_frame>Four weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healing time of conjunctival epithelium</measure>
    <time_frame>Four weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amplitude of eye movement</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complication</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Pterygium</condition>
  <arm_group>
    <arm_group_label>MMC after Extensive pterygium excision</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intraoperative mitomycin C (0.02%) will be applied for 5 minutes after extensive pterygium excision. The conjunctival defect will be left bare with no graft on.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMT after Extensive Pterygium Excision</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amniotic membrane transplantation will be applied to cover the conjunctival defect after extensive pterygium excision. No mitomycin C will be applied.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MMC</intervention_name>
    <description>Intraoperative mitomycin C (0.02%) will be applied for 5 minutes after extensive pterygium excision.</description>
    <arm_group_label>MMC after Extensive pterygium excision</arm_group_label>
    <other_name>Intraoperative Mitomycin C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AMT</intervention_name>
    <description>Amniotic membrane transplantation will be applied to cover the conjunctival defect after extensive pterygium excision.</description>
    <arm_group_label>AMT after Extensive Pterygium Excision</arm_group_label>
    <other_name>Amniotic membrane transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Extensive pterygium excision</intervention_name>
    <description>Partial conjunctiva and a extensive area of tenon's membrane underneath will be removed after the excision of pterygium.</description>
    <arm_group_label>MMC after Extensive pterygium excision</arm_group_label>
    <arm_group_label>AMT after Extensive Pterygium Excision</arm_group_label>
    <other_name>Extended pterygium excision</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary pterygium

          -  Willingness to participate in research project and to attend research time

          -  Adults (age 18 to 80 years old)

          -  Patients must not meet any of the following exclusion criteria

        Exclusion Criteria:

          -  Pregnant or breast-feeding women

          -  Significant ocular surface disease apart from pterygium, such as Sjogren's Syndrome
             and dacryocystitis

          -  Patients with significant ocular or lid pathology, such as infection,glaucoma and
             exposure keratitis

          -  Patients with a history of other previous ocular surgeries or trauma

          -  Patients with allergy to mitomycin C,tobramycin or local anesthetics

          -  Poor general health

          -  Recurrent pterygium
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiyou Zhou, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shiyou Zhou, M.D., Ph.D.</last_name>
    <phone>86-02087331540</phone>
    <email>zhoushiy@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tao Zhou, M.D.</last_name>
    <phone>86-18013220133</phone>
    <email>taochou_tony@foxmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xi'an Eye Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sichuan Ganzi Autonomous Prefecture People's Hospital</name>
      <address>
        <city>Ganzi</city>
        <state>Sichuan</state>
        <zip>626000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Fourth Affiliated Hospital, Kunming Medical University</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 5, 2014</lastchanged_date>
  <firstreceived_date>March 31, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Shiyou Zhou</investigator_full_name>
    <investigator_title>M.D., Ph.D</investigator_title>
  </responsible_party>
  <keyword>Pterygium</keyword>
  <keyword>Mitomycin C</keyword>
  <keyword>Amniotic membrane transplantation</keyword>
  <keyword>Extensive pterygium excision</keyword>
  <keyword>Multi-center randomized clinical trial</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pterygium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
